202 related articles for article (PubMed ID: 22184400)
1. The future of drug development in urothelial cancer.
Dreicer R
J Clin Oncol; 2012 Feb; 30(5):473-5. PubMed ID: 22184400
[No Abstract] [Full Text] [Related]
2. The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract.
de Mulder PH; Sternberg CN; van Oosterom AT; Fossa SD
Semin Oncol; 1994 Feb; 21(1 Suppl 1):65-9. PubMed ID: 7512278
[No Abstract] [Full Text] [Related]
3. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Powles T; Bellmunt J; Comperat E; De Santis M; Huddart R; Loriot Y; Necchi A; Valderrama BP; Ravaud A; Shariat SF; Szabados B; van der Heijden MS; Gillessen S;
Ann Oncol; 2024 Jun; 35(6):485-490. PubMed ID: 38490358
[No Abstract] [Full Text] [Related]
4. Pembrolizumab plus enfortumab vedotin in urothelial cancer.
Santoni M; Takeshita H; Massari F; Bamias A; Cerbone L; Fiala O; Mollica V; Buti S; Santoni A; Bellmunt J
Nat Rev Urol; 2024 Jul; 21(7):387-388. PubMed ID: 38267716
[No Abstract] [Full Text] [Related]
5. Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
Culine S; Sellam Z; Bouaita L; Assaf E; Delbaldo C; Verlinde-Carvalho M; Pouessel D
Anticancer Res; 2012 Sep; 32(9):3949-52. PubMed ID: 22993342
[TBL] [Abstract][Full Text] [Related]
6. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
[TBL] [Abstract][Full Text] [Related]
7. Towards effective adjuvant treatment for urothelial cancer.
Siefker-Radtke AO; Gao J
Lancet Oncol; 2015 Jan; 16(1):9-10. PubMed ID: 25498220
[No Abstract] [Full Text] [Related]
8. Systemic chemotherapy of transitional cell carcinoma of the urothelium.
Chun HG; Dorr FA
Cancer Treat Res; 1989; 42():151-74. PubMed ID: 2577102
[No Abstract] [Full Text] [Related]
9. The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
Bertucci F; de Nonneville A; Finetti P; Cohendet A; Guille A; Mamessier E
Ann Oncol; 2024 May; 35(5):477-478. PubMed ID: 38364991
[No Abstract] [Full Text] [Related]
10. Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
Benjamin DJ; Lythgoe MP; Rezazadeh A
BJU Int; 2023 Jun; 131(6):691-693. PubMed ID: 36877951
[No Abstract] [Full Text] [Related]
11. Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Kondo T
Int J Urol; 2024 May; 31(5):560-561. PubMed ID: 38424666
[No Abstract] [Full Text] [Related]
12. Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Ishihara H; Takagi T
Int J Urol; 2024 May; 31(5):559-560. PubMed ID: 38366784
[No Abstract] [Full Text] [Related]
13. Therapeutic experience of advanced urothelial tract tumors.
Nakada T; Akiya T; Yoshikawa M; Umeda K; Katayama T
Hinyokika Kiyo; 1985 Apr; 31(4):601-6. PubMed ID: 4041118
[TBL] [Abstract][Full Text] [Related]
14. Re: Immediate versus Deferred Chemotherapy after Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-Label, Randomised Phase 3 Trial.
Chang SS
J Urol; 2016 Jan; 195(1):63-4. PubMed ID: 26699956
[No Abstract] [Full Text] [Related]
15. Adjuvant chemotherapy in locally advanced bladder cancer.
Lu K
Lancet Oncol; 2015 Mar; 16(3):e103-4. PubMed ID: 25752555
[No Abstract] [Full Text] [Related]
16. Progress in treatment of advanced urothelial tract tumors.
Yagoda A
J Clin Oncol; 1985 Nov; 3(11):1448-50. PubMed ID: 3903061
[No Abstract] [Full Text] [Related]
17. Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Goto Y
Int J Urol; 2023 Sep; 30(9):704. PubMed ID: 36482811
[No Abstract] [Full Text] [Related]
18. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
Rosenberg JE; von der Maase H; Seigne JD; Mardiak J; Vaughn DJ; Moore M; Sahasrabudhe D; Palmer PA; Perez-Ruixo JJ; Small EJ
Cancer; 2005 May; 103(10):2035-41. PubMed ID: 15812833
[TBL] [Abstract][Full Text] [Related]
19. Systemic chemotherapy for urothelial cancer.
Sonpavde G; Hutson TE; Berry WR
Clin Genitourin Cancer; 2006 Jun; 5(1):34-42. PubMed ID: 16859577
[TBL] [Abstract][Full Text] [Related]
20. [First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)].
Rexer H; Ohlmann CH; Retz M
Urologe A; 2017 May; 56(5):659-661. PubMed ID: 28349185
[No Abstract] [Full Text] [Related]
[Next] [New Search]
